Breast Cancer pp 155-170 | Cite as

Current Status of Axillary Node Dissection

  • Nora Hansen
  • Monica Morrow
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA)

Abstract

Breast cancer is the most common cancer in women in the United States, and the mainstay of treatment for breast cancer is surgical resection. The type and extent of resection have changed dramatically over the last 40 years, with radical resections, popular during the 1950s and 1960s, being replaced by a more conservative approach as better understanding of the systemic nature of breast cancer has evolved. Regardless of whether a breast-conserving procedure or mastectomy is undertaken, dissection of the axillary nodes is a standard part of surgical therapy.

Keywords

Obesity Catheter Estrogen Citrate Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fisher B, Wolmark N, Bauer M, et al. The accuracy of clinical nodal staging and of limited axillary lymph node dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765–771.PubMedGoogle Scholar
  2. 2.
    Haagensen C. Clinical classification and choice of treatment. In: Haagensen C (ed) Diseases of the Breast, 3rd ed. Philadelphia: Saunders, 1986;617–668.Google Scholar
  3. 3.
    March DE, Wechsler RJ, Kurtz AB, et al. CT-pathologic correlation of axillary lymph nodes in breast cancer. J Comput Assist Tomogr 1991;15:440–444.PubMedCrossRefGoogle Scholar
  4. 4.
    Nieweg O, Kim E, Wong W, et al. Positron emission with fluoro 18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920–3925.PubMedCrossRefGoogle Scholar
  5. 5.
    Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204–1209.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosen PP, Lesser ML, Kinne DW, et al. Discontinuous or “skip” metastases in breast carcinoma: analysis of 1228 axillary lymph node dissections. Ann Surg 1983;197:276–283.PubMedCrossRefGoogle Scholar
  7. 7.
    Veronesi U, Rilke F, Luini A, et al. Distribution of axillary node metastases by level of invasion. Cancer 1987;59:682–687.PubMedCrossRefGoogle Scholar
  8. 8.
    Danforth DN Jr, Findlay PA, McDonald HD, et al. Complete axillary lymph node dissection for stage I—II carcinoma of the breast. J Clin Oncol 1985;4:655–662.Google Scholar
  9. 9.
    Pigott J, Nicholas R, Maddox WA, et al. Metastases to the upper levels of the axillary nodes in carcinoma of the breast and its implications for nodal sampling procedures. Surg Gynecol Obstet 1984;158:255–259.PubMedGoogle Scholar
  10. 10.
    National Institutes of Health Consensus Conference: treatment of early stage breast cancer. JAMA 1991;265:391–395.Google Scholar
  11. 11.
    Kissin MW, Thompson EM, Price AB, et al. The inadequacy of axillary sampling in breast cancer. Lancet 1982;1:1210–1212.PubMedCrossRefGoogle Scholar
  12. 12.
    Steele RJ, Forrest AP, Gibson T, et al. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomized trial. Br J Surg 1985;72:368–369.PubMedCrossRefGoogle Scholar
  13. 13.
    Graversen HP, Blichert-Toft M, Andersen JA, et al. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988;14:407–412.PubMedGoogle Scholar
  14. 14.
    Fisher B, Redmond C, Fisher ER, et al. Ten year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with and without radiation. N Engl J Med 1985;312:674–681.PubMedCrossRefGoogle Scholar
  15. 15.
    Osborne MP, Ormiston N, Harmer CL, et al. Breast conservation in the treatment of early breast cancer: a 20 year follow-up. Cancer 1984;53:349–355.PubMedCrossRefGoogle Scholar
  16. 16.
    Axelsson CK, Mouridsen HT, Zedeler K. Axillary lymph node dissection of level I and II lymph nodes is important in breast cancer classification: the Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;8A:1415–1418.CrossRefGoogle Scholar
  17. 17.
    Lythgoe JP, Pamer MK. Manchester regional breast study: five and 10 year results. Br J Surg 1982;69:693–696.PubMedCrossRefGoogle Scholar
  18. 18.
    Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early stage breast carcinoma. J Clin Oncol 1991;9:988–996.PubMedGoogle Scholar
  19. 19.
    Fowble B, Solin LJ, Schultz DJ, et al. Frequency, sites of relapse and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 1989;17:703–710.PubMedCrossRefGoogle Scholar
  20. 20.
    Haffty BG, Fischer D, Fischer JJ. Regional nodal irradiation in the conservative treatment of breast cancer. Int J Radiat Oncol Biol Phys 1990;19:859–865.PubMedCrossRefGoogle Scholar
  21. 21.
    Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary lymph node dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 1992:339:1245–1248.PubMedCrossRefGoogle Scholar
  22. 22.
    Ivens D, Hoe AL, Podd CR, et al. Assessment of morbidity from complete axillary lymph node dissection. Br J Cancer 1991;66:136–138.CrossRefGoogle Scholar
  23. 23.
    Werner R, McCormick B, Petrek J, et al. Arm edema in conservatively managed breast cancer: obesity is a major predictive factor. Radiology 1991;180:177–184.PubMedGoogle Scholar
  24. 24.
    Ryttov N, Holm NV, Quist N, et al. Influence of adjuvant irradiation on the development of late arm edema and impaired shoulder mobility after mastectomy for carcinoma of the breast. Acta Oncol 1988;27:667–670.PubMedCrossRefGoogle Scholar
  25. 25.
    Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11:1636–1644.Google Scholar
  26. 26.
    Hladiuk M, Huuchroft S, Temple W, et al. Arm function after axillary lymph node dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol 1992;50:47–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Pezner R, Patterson M, Hill L. Arm edema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol 1986;12:2079–2083.CrossRefGoogle Scholar
  28. 28.
    Aitken D, Minton J. Complications associated with mastectomy. Surg Clin North Am 1983;63:1331–1352.PubMedGoogle Scholar
  29. 29.
    Wood K. Intercostobrachial nerve entrapment syndrome. South Med J 1978;71:662–663.PubMedCrossRefGoogle Scholar
  30. 30.
    Siegel B, Mayzel K, Love S. Level I and level II axillary lymph node dissection in the treatment of early stage breast cancer. Arch Surg 1990;125:1144–1149.PubMedGoogle Scholar
  31. 31.
    Somers R, Jablon L, Kaplan M, et al. The use of closed suction drainage catheter after lumpectomy and axillary node dissection for breast cancer: a randomized trial. Ann Surg 1992;215:146–149.PubMedCrossRefGoogle Scholar
  32. 32.
    Morrow M. Axillary node dissection: what role in managing breast cancer? Contemp Oncol 1994;8:16–27.Google Scholar
  33. 33.
    Wilson RE, Donegan WL, Mettlin C, et al. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet 1984;159:309–318.PubMedGoogle Scholar
  34. 34.
    Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181–187.PubMedCrossRefGoogle Scholar
  35. 35.
    Winchester DJ, Menck HR, Fremgen AM, et al. Selection criteria for axillary lymph node dissection in breast cancer. Presented at the 48th Cancer Symposium of the Society for Surgical Oncology, Houston, March 1994.Google Scholar
  36. 36.
    Silverstein MJ, Gierson ED, Waisman JR, et al. Axillary lymph node dissection for T1a breast carcinomas: is it indicated? Cancer 1994;73:664–667.PubMedCrossRefGoogle Scholar
  37. 37.
    Winchester DJ, Menck HR, Bland K, et al. Axillary lymph node metastases in an audit analysis of T1a breast cancers. Presented at the 50th Cancer Symposium of the Society of Surgical Oncology, Chicago, March 1997.Google Scholar
  38. 38.
    Silverstein MJ, Waisman JR, Gierson ED, et al. Can axillary lymph node dissection be eliminated for selected patients with invasive breast cancer by using a combination of tumor size and palpability to predict nodal positivity? Proc Am Soc Clin Oncol 1994;13:56–61.Google Scholar
  39. 39.
    Walls J, Boggis CR, Wilson M, et al. Treatment of the axilla in patients with screen-detected breast cancer. Br J Surg 1993;80:436–438.PubMedCrossRefGoogle Scholar
  40. 40.
    Harris JR, Morrow M. Local management of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996;487–547.Google Scholar
  41. 41.
    Wilhelm MC, Edge SB, Cole D, et al. Nonpalpable invasive breast cancer. Ann Surg 1992;213:600–605.CrossRefGoogle Scholar
  42. 42.
    Chadha M, Chabon AB, Friedmann P, et al. Predictors of axillary lymph node metastases in patients with T1 breast cancer: a multivariate analysis. Cancer 1994;73:350–353.PubMedCrossRefGoogle Scholar
  43. 43.
    Ravdin PM, DeLaurentis M, Vendely T, et al. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 1994;86:1771–1775.PubMedCrossRefGoogle Scholar
  44. 44.
    Ashikari R, Huvos AG, Snyder RE. Prospective study of non-infiltrating carcinoma of the breast. Cancer 1977;39:435–439.PubMedCrossRefGoogle Scholar
  45. 45.
    Westbrook KC, Gallager HS. Intraductal carcinoma of the breast: a comparative study. Am J Surg 1975;130:667–670.PubMedCrossRefGoogle Scholar
  46. 46.
    Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139–147.PubMedCrossRefGoogle Scholar
  47. 47.
    Von Reuden DG, Wilson RE. Intraductal carcinoma of the breast. Surg Gynecol Obstet 1984;158:105–111.Google Scholar
  48. 48.
    Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208) cases: clinical factors influencing treatment choice. Cancer 1990;66:102–108.PubMedCrossRefGoogle Scholar
  49. 49.
    Solin LJ, Fowble BL, Schultz DJ, et al. Definitive irradiation for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys 1990;19:843–850.PubMedCrossRefGoogle Scholar
  50. 50.
    Fisher ER, Sass R, Risher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6), intraductal carcinoma (DCIS). Cancer 1986;57:197–208.PubMedCrossRefGoogle Scholar
  51. 51.
    Brown PW, Silverman J, Owens E, et al. Intraductal “noninfiltrating” carcinoma of the breast. Arch Surg 1976;111:1063–1067.PubMedGoogle Scholar
  52. 52.
    Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990;125:1298–1302.PubMedGoogle Scholar
  53. 53.
    Solin LJ, Fowble BL, Yeh IT, et al. Microinvasive ductal carcinoma of the breast treated with breast conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992;23:961–968.PubMedCrossRefGoogle Scholar
  54. 54.
    Frazier TG, Copeland EM, Gallagher HS, et al. Prognosis and treatment in minimal breast cancer. Am J Surg 1977;133:697–701.PubMedCrossRefGoogle Scholar
  55. 55.
    Nevin JE, Pinzon G, Moran TJ, et al. Minimal breast cancer. Am J Surg 1980;139:357–359.PubMedCrossRefGoogle Scholar
  56. 56.
    Schuh ME, Nemoto T, Penetrante RB, et al. Intraductal carcinoma: analysis of presentation, pathologic findings and outcome of disease. Arch Surg 1986;121:1303–1307.PubMedCrossRefGoogle Scholar
  57. 57.
    Kinne DW, Petrek JA, Osborne MP, et al. Breast carcinoma in situ. Arch Surg 1989; 124:333–336.Google Scholar
  58. 58.
    McDivitt RW, Boyce W, Gersell D. Tubular carcinoma of the breast: clinical and pathological observations concerning 135 cases. Am J Surg Pathol 1982;6:401–411.PubMedCrossRefGoogle Scholar
  59. 59.
    Peters GN, Wolff M, Haagensen CD. Tubular carcinoma of the breast: clinical pathologic correlations based on 100 cases. Ann Surg 1981;193:138–149.PubMedCrossRefGoogle Scholar
  60. 60.
    Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy: Early Breast Cancer Trialist’s Collaborative Group. Lancet 1992;339:1–15.Google Scholar
  61. 61.
    Berlanger D, Moore M, Tannock I. How American oncologists treat breast cancer: an assessment of the influence of clinical trials. J Clin Oncol 1991;9:7–16.Google Scholar
  62. 62.
    Goldhirsh A, Wood WC, Senn HJ, et al. Meeting highlight: international consensus panel on treatment of primary breast cancer. J Natl Cancer Inst 1995;87:1441–1445.CrossRefGoogle Scholar
  63. 63.
    Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996;347:1066–1071.PubMedCrossRefGoogle Scholar
  64. 64.
    Morton D, Wen DR, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.PubMedGoogle Scholar
  65. 65.
    Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;229:391–401.CrossRefGoogle Scholar
  66. 66.
    Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:399–401.CrossRefGoogle Scholar
  67. 67.
    Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818–1822.PubMedCrossRefGoogle Scholar
  68. 68.
    Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335–340.PubMedCrossRefGoogle Scholar
  69. 69.
    Winchester DP, Menck HR, Osteen RT, et al. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol 1995;2:207–213.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1999

Authors and Affiliations

  • Nora Hansen
  • Monica Morrow

There are no affiliations available

Personalised recommendations